



Proventa International's 11th Annual

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING EAST COAST USA 2024

📅 Tuesday, 14th May 2024 📍 Hyatt Regency Princeton

Pushing our understanding of the physiological context and quality of drug target characterisation, validation, and safety profiling throughout the preclinical space

BOOK NOW

NEW FOR 2024:

Strategic
Partnerships,
Investment &
Collaborations

Featuring Industry Leaders and Decision Makers:



Marcie
Glicksman
VP Biology
**EnClear
Therapies**



Angela L.
Huang
Founder and
President
**Tempo
Bioscience**



Claudette
Fuller
Vice President,
Head of Non-Clinical
Safety & Toxicology
Genmab



Mark
Tornetta
Vice President of
Biologics Discovery
(TavoSelect)
**Tavotek
Biotherapeutics**



Nikolaos
Tezapsidis
President &
CEO
Neurotez Inc.



Paul
Kayne
Vice President,
Biological
Sciences
**Palatin
Technologies**



20
ROUNDTABLE
DISCUSSIONS



5
TRACKS



2
KEYNOTE
PRESENTATIONS



1
PANEL
DISCUSSION



1
LOCATION



HYATT
REGENCY



What Makes
Our Strategy
Meetings
So Unique?

Proud to Partners with:

curia

PELAGO
BIOSCIENCE

Core Life Analytics

NovAliX



Scan to Register

PROVENTA
INTERNATIONAL

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com

Proventa International

@proventaintl

@proventainternational

Proventa International's Strategy Meetings are a completely unique experience.

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS
STRATEGY MEETING EAST COAST USA 2024
📅 Tuesday 14th May 2024 📍 Hyatt Regency Princeton

We're committed to delivering long-term value across our extensive life science network. Through our carefully crafted meetings, collaborative experiences and services Proventa International can offer you the perfect opportunity to meet your business goals, whatever they may be.



Our Vision

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.



Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format



ROUNDTABLE DISCUSSIONS

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.



PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.



INNOVATIVE SOLUTIONS

The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.




STRATEGIC NETWORKING

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

Seniority of Attendees

- Director Level
- President / VP
- Department Head
- Other
- Team Lead
- C-Level
- Scientist
- Academia
- Manager
- Biology Specialist



Biology

- ✓ Biology
- ✓ R&D
- ✓ Drug Discovery
- ✓ Bioinformatics
- ✓ DMPK
- ✓ ADME
- ✓ Toxicology
- ✓ Structural Biology
- ✓ Pre-Clinical

Bioinformatics

- ✓ CIO
- ✓ Head of Lab
- ✓ Bioinformatics
- ✓ Clinical Data
- ✓ R&D IT
- ✓ Data Sciences
- ✓ Translational Medicine
- ✓ Digital Transformation
- ✓ Omics
- ✓ AI/ML
- ✓ Biostatistics
- ✓ Analytics
- ✓ Genome Informatics
- ✓ Security & Privacy
- ✓ Data Management

Meet Investors

- ✓ Venture Capital
- ✓ Private Equity
- ✓ Large Pharma/Biotech
- ✓ Corporate Venture Capital
- ✓ Institutional
- ✓ High Net Worth
- ✓ Family Office/Private Wealth
- ✓ Government Organisation/Sovereign Wealth Fund
- ✓ Angel

BOOK NOW!

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

✉ info@proventainternational.com
🌐 Proventa International

🐦 [@proventaintl](https://twitter.com/proventaintl)
🌐 [@proventainternational](https://www.proventainternational.com)



Facilitator Faculty

**DRUG DISCOVERY BIOLOGY
& BIOINFORMATICS**
STRATEGY MEETING EAST COAST USA 2024
📅 Tuesday 14th May 2024 📍 Hyatt Regency Princeton



Douglas Kitchen
Research Fellow,
Medicinal Chemistry
Curia



Greg Williams
Senior Research Scientist II,
Cellular Assay Technologies
Curia



Steven Ring
Senior Research Scientist
II, Drug Metabolism and
Pharmacokinetics
Curia



Aaron Mackey
Former SVP,
AI & Data Science
Sonata Therapeutics



Abhijat Vatsyayan
Head of Artificial
Intelligence
Taiho Oncology



Andrew Zhang
Director, Head of
Chemical Biology
AstraZeneca



Angela Huang
Founder & President
Tempo Bioscience



Claudette Fuller
Vice President,
Head of Non-Clinical
Safety & Toxicology
Genmab



Ernane Souza,
PhD, RPh
Assistant Director,
Translational PKPD
and DMPK
**Supernus
Pharmaceuticals Inc**



Frank Leu
Founder & Managing
Member/Managing
Member
**BioPharMatrix LLC/
Novapeutics LLC**



**Gunaretnam
Rajagopal**
Venture Partner
SamSara Biocapital



Marcie Glicksman
VP Biology
EnClear Therapies



Mark Tornetta
Vice President of
Biologics Discovery
(TavoSelect)
**Tavotek
Biotherapeutics**



Nikolaos Tezapsidis
President & CEO
Neurotez Inc.



Paul Kayne
Vice President,
Biological Sciences
Palatin Technologies

BOOK NOW!

proventainternational.com

📞 UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

✉ info@proventainternational.com
🌐 Proventa International

🐦 @proventaintl
🌐 @proventainternational



2024 Sponsors

**DRUG DISCOVERY BIOLOGY
& BIOINFORMATICS**
STRATEGY MEETING EAST COAST USA 2024
📅 Tuesday 14th May 2024 📍 Hyatt Regency Princeton

LEAD SPONSOR



Curia is a Contract Research, Development and Manufacturing Organization with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecules offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state of the art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com

PARTNERING SPONSORS



KEY OPINION LEADER



BOOK NOW!

proventainternational.com

📞 UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

✉️ info@proventainternational.com
🌐 Proventa International

🐦 @proventaintl
📘 @proventainternational































Agenda at a Glance

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING EAST COAST USA 2024

Tuesday 14th May 2024 Hyatt Regency Princeton

	TRACK 1	TRACK 2	TRACK 3	TRACK 4	 TRACK 5
TIME	TARGET IDENTIFICATION & HIT VALIDATION	DMPK / ADME & TOXICOLOGY	IN VIVO AND IN VITRO PHARMACOLOGY	IN SILICO BIOLOGY / AI & ML / BLOCKCHAIN AND BIOINFORMATICS / DATA INTEGRATION & DATA MINING	STRATEGIC PARTNERSHIPS, INVESTMENT & COLLABORATIONS
EST					
08:00 - 08:30	BREAKFAST & REGISTRATION				
08:30 - 09:00	OPENING KEYNOTE PRESENTATION				
	 PRESENTER: Andrew Zhang, <i>Director, Head of Chemical Biology, AstraZeneca</i>				
09:00 - 10:00	Maximizing the potentials of multi-omics in target identification and safety profiling  Paul Kayne, <i>Vice President, Biological Sciences, Palatin Technologies</i>	Advancing Drug Discovery and Safety Assessment with AI/ML: Where we are and where we're going  Claudette Fuller, <i>Vice President, Head of Non-Clinical Safety & Toxicology, Genmab</i>	Latest approaches and trends for improving nonclinical studies  Angela Huang, <i>Founder and President, Tempo Bioscience</i>	Harnessing the promise of generative AI to transform drug discovery hence forward  Aaron Mackey, <i>Former SVP, AI & Data Science, Sonata Therapeutics</i>	Forming Strategic Partnerships: Collaboration or M&A?  Nikolaos Tezapsidis, <i>President & CEO, Neurotez Inc.</i>
10:00 - 10:05	REFRESHMENT BREAK				
10:05 - 10:25	NETWORKING / 1-1 MEETINGS				
10:25 - 10:45	NETWORKING / 1-1 MEETINGS				
10:45 - 11:05	NETWORKING / 1-1 MEETINGS				
11:10 - 12:10	Probing ways to access greater target space and expand the druggable genome to a larger therapeutic area to discover new drugs  Greg Williams, <i>Senior Research Scientist II, Cellular Assay Technologies, CURIA</i> 	Integrating breakthroughs in In Silico, In Vivo And In Vitro Pharmacology To Enhance ADMET Modeling  Steven Ring, <i>Senior Research Scientist II, Drug Metabolism and Pharmacokinetics, CURIA</i> 	Identifying the rein of using animal models in pre-clinical testing and combining current in vitro technique to achieve desired result 	Leveraging AI, target selection technologies/ strategies and infrastructure tools to support computational biology  Douglas Kitchen, <i>Research Fellow, Medicinal Chemistry, CURIA</i> 	Strategic Partnerships, Investment & Collaborations in drug development  Frank Leu, <i>Founder & Managing Member/ Managing Member, BioPharMatrix LLC/ Novapeutics LLC</i>
12:15 - 13:15	Reducing attrition rate by employing groundbreaking technologies at discovery stage and accelerate the process  Mark Tornetta, <i>Vice President of Biologics Discovery (TavoSelect), Tavotek Biotherapeutics</i>	Exploring the use of organ-on-a-chip and other microphysiological systems for high-throughput toxicity screening, ADME studies, and prediction of drug safety profiles	Tackling In Vivo Complexity: Strategies for Overcoming Assay Challenges  Marcie Glicksman, <i>VP Biology, EnClear Therapies</i>	Current adoption and best use of disruptive techs (blockchain, AI, and ML) in drug discovery and development  Frank Leu, <i>Founder & Managing Member/ Managing Member, BioPharMatrix LLC/ Novapeutics LLC</i>	Challenges of developing ADCs and Immunomodulatory Bispecific Biologics
13:15 - 14:00	NETWORKING LUNCH				
14:00 - 14:20	NETWORKING / 1-1 MEETINGS				
14:20 - 14:40	NETWORKING / 1-1 MEETINGS				
14:40 - 15:10	 AFTERNOON KEYNOTE PRESENTATION 				
15:10 - 16:10	Navigating Target Selection and Validation in Drug Discovery: Criteria, Strategies and Models  Marcie Glicksman, <i>VP Biology, EnClear Therapies</i>	Artificial Intelligence, ADME/Tox prediction, PBPK modeling, and Data Management Strategies for early drug development.  Ernane Souza, <i>PhD, RPh, VAssistant Director, Translational PKPD and DMPK, Supernus Pharmaceuticals Inc</i>	In vitro, organoid, and organ-on-chip tools in drug discovery	Decoding Omics Data Interpretation, Integration, and Application in Drug Discovery through the lense of In Silico Biology  Abhijat Vatsyayan, <i>Head of Artificial Intelligence, Taiho Oncology Inc</i>	Fundraising and Partnership Opportunities in the current BioPharma Industry  Angela L. Huang, <i>Founder and President, Tempo Bioscience</i>
16:10 - 16:30	AFTERNOON REFRESHMENT BREAK				
16:30 - 17:00	PANEL DISCUSSION Tackling the pros and cons of different financing blueprint: go-to-clinic vs go-to-market vs go-to-fundraising strategies and the criteria to determine which program an organization can adapt  CHAIRPERSON: Gunaretnam Rajagopal, <i>Venture Partner, Samsara Biocapital</i>  PANELIST: Nikolaos Tezapsidis, <i>President & CEO, Neurotez</i>				
17:00 - 18:00	DRINKS & CANAPES RECEPTION				

Event Day | Keynote Presentations

A great way to open the roundtable discussions is through a timely presentation from a top-tier biotech/pharmaceutical company. Listen as we hear this 30-minute exposition on this meeting's pressing topic.

DRUG DISCOVERY BIOLOGY
& BIOINFORMATICS

STRATEGY MEETING EAST COAST USA 2024

Tuesday 14th May 2024 Hyatt Regency Princeton

08:30 - 09:00 ET

OPENING KEYNOTE PRESENTATION

Topic TBC



Andrew Zhang

Director, Head of Chemical Biology
AstraZeneca



ABOUT THE SPEAKER

Andrew Zhang is the Director and Head of Chemical Biology at AstraZeneca. He joined AstraZeneca in 2013 and his team's remit is using chemical probes and mass spectrometry-based discovery proteomics for deconvoluting the mechanism of drug target engagement towards identifying drivers of efficacy and adverse safety events. Andrew's scientific career started at the University of California, Berkeley, where he obtained a B.S. in Chemistry and a B.A. in Molecular and Cell Biology, and he received his Ph.D. with Professor David Spiegel at Yale working on small molecule immunomodulators. Andrew trained as a postdoctoral fellow at the Ontario Institute for Cancer Research (Toronto, Canada) with Dr. Rima Al-awar.

14:40 - 15:10 ET

AFTERNOON KEYNOTE PRESENTATION

Topic TBC



Speaker TBC

curia



ABOUT THE SPEAKER

Speaker TBC

16:30 - 17:00 ET

PANEL DISCUSSION

Tackling the pros and cons of different financing blueprint: go-to-clinic vs go-to-market vs go-to-fundraising strategies and the criteria to determine which program an organization can adapt



CHAIRPERSON

Gunaretnam Rajagopal

Venture Partner
Samsara BioCapital



PANEL

Nikolaos Tezapsidis

President & CEO
Neurotez

ABOUT THE SPEAKER

Guna's expertise encompasses the fields of Data Sciences, AI/Machine Learning, Bioinformatics, Computational, Systems Biology & Pharmacology, Genetics & Genomics, High Performance Computing and Theoretical & Computational Physics. He has led global initiatives focused on advancing cross-disciplinary basic research, translational & clinical programs in collaboration with academia and national/international pre-competitive consortiums. Guna's academic career spans undergraduate degree from the University of Malaya (1986), PhD in Computational & Theoretical Physics from Georgia Tech (1987-1991), post-doctoral training at the Cavendish Laboratory, University of Cambridge, rising to Assistant Director of Research and elected a Fellow of Jesus College Cambridge (1991-2000). He was the founding Executive Director of the Bioinformatics Institute at the BIOPOLIS, Singapore (2000-2007), led the Bioinformatics & Systems Biology program at the Rutgers Cancer Institute of New Jersey with a joint appointment as Adjunct Professor at the Robert Wood Johnson Medical School and as a Member of Advanced Studies in Princeton (2007-2012). He joined Janssen R&D to lead efforts to develop and deploy Computational Analytics, Informatics and Data Science capabilities to support global discovery, translational, development and clinical programs (2012-2022). He retired as Scientific Fellow and Global Head of Computational Sciences and joined Samsara Biocapital as a Venture Partner.

BOOK NOW!

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com

Proventa International

@proventaintl

@proventainternational



Event Day

TRACK 1 Target Identification & Hit Validation

Improving efficiency in finding novel therapeutic targets continues to be an immediate priority and hurdle in the pharma and biotech industry. This track aims to explore the undruggable space for utilizing AI/ML, optimizing target identification pathways and many more. How can we ensure the next druggable target frontier stays viable?

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING EAST COAST USA 2024

14th May 2024, Tuesday Hyatt Regency Princeton

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
[See Page 6](#)

09:00 - 10:00 ET ROUNDTABLE 1

Maximizing the potentials of multi-omics in target identification and safety profiling

- How to leverage Multi-omics Data to Derive Actionable Insights
- Disease subtyping and classification
- Prediction of biomarkers: diagnostics, disease drivers, drug efficacy, adverse events, and more
- Deriving insights into disease biology



Paul Kayne
Vice President, Biological Sciences
Palatin Technologies

ABOUT THE SPEAKER

Dr. Paul Kayne has an extensive track record of innovation enabling pharmaceutical R&D and life-cycle management. He is currently VP of Biological Sciences at Palatin, a company focusing on resolving inflammatory diseases. Prior to joining Palatin, Dr. Kayne held several roles at Bristol-Myers Squibb, most recently Head of Discovery Genomics & Proteomics. Previously, Dr. Kayne built one of the earliest microarray teams while at SmithKline Beecham and was a member of the Research Faculty at the California Institute of Technology. Dr. Kayne received his Ph.D. in molecular biology from the UCLA and his B.A. in molecular biology/biochemistry from the UCSB.

10:00 - 11:05 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

Probing ways to access greater target space and expand the druggable genome to a larger therapeutic area to discover new drugs



- How can we leverage emerging technologies and platforms to explore a broader target space for drug discovery?
- What strategies can be employed to validate hits efficiently and effectively, ensuring they have therapeutic potential?
- How important is it to consider target specificity and selectivity in the drug discovery process, and what methods can be used to assess these factors?
- What innovative screening approaches or assays are emerging to access unexplored target space and accelerate hit identification?
- What role does computational modeling and artificial intelligence play in identifying novel drug targets and predicting hit efficacy?
- How can we overcome challenges related to target identification in complex diseases with multiple pathways and targets?
- How can we address the issue of target redundancy and optimize strategies to prioritize targets with the highest therapeutic potential?



Greg Williams
Senior Research Scientist II,
Cellular Assay Technologies
Curia



ABOUT THE SPEAKER
Speaker TBC

12:15 - 13:15 ET ROUNDTABLE 3

Reducing attrition rate by employing groundbreaking technologies at discovery stage and accelerate the process

- Application of disease relevance during hit selection and hit screening- HCS?
- Implement assays that provide some sort of TI (therapeutic index) early into the discovery process- Evaluate off disease interactions along with potency/efficacy?
- Correlation between in vitro and in vivo assessments- Is ex vivo the answer?



Mark Tornetta
Vice President of Biologics Discovery (TavoSelect)
Tavotek Biotherapeutics

ABOUT THE SPEAKER

Mark Tornetta has 30+ years of lead discovery experience in the biopharmaceutical and biotechnology sectors. The first 10+ years he performed antibody engineering and small molecule screening for de-orphanizing GPCR targets at SmithKline Beecham. The next 18+ years at Centocor/J&J he was part of an antibody engineering team that implemented 2 phage display technologies that generated thousands of candidates to hundreds of targets. His most accomplished project was discovering an antibody currently in the clinic at GSK for pulmonary inflammatory indications. The last 3 years at Tavotek he implemented a unique antibody generation platform called TAVOSelect which has generated thousands of VHOs to many IO targets

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION
[See Page 6](#)

15:10 - 16:10 ET ROUNDTABLE 4

Navigating Target Selection and Validation in Drug Discovery: Criteria, Strategies and Models

- What criteria should one use to select a disease target?
- Has the definition of a "druggable" target changed with the advent of gene therapy approaches?
- What are the best strategies to validate hits?
- What new models are available for validation of hits?



Marcie Glicksman
VP Biology
EnClear Therapies

ABOUT THE SPEAKER

Marcie Glicksman, Ph.D. Vice President, Biology at EnClear Therapies. For the past 30 years, Dr. Glicksman has been dedicated to developing better therapeutics for the nervous system and other therapeutic areas. Her efforts include 8 drugs entering the clinic and 2 marketed drugs. She has worked in both the biopharmaceutical industry and academics. In her career, she has broad experience including preclinical animal studies and toxicology. Dr. Glicksman received a bachelor's degree from Brown University and a Ph.D. degree in Neuroscience from Washington University. Dr. Glicksman has over 80 publications and more than 16 issued patents.

16:10 - 16:30 ET AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 ET PANEL DISCUSSION
[See Page 6](#)

17:00 - 18:00 ET DRINKS & CANAPES RECEPTION

BOOK NOW!

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com
Proventa International

@proventaintl
@proventainternational



Event Day

TRACK 2

DMPK / ADME & Toxicology

A key idea in biology is that structure, to a large extent, dictates function. The rapid development of sensitive biophysical methods and emerging technologies that interrogate compound properties and mechanisms of action is transforming drug discovery.

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
[See Page 6](#)

09:00 - 10:00 ET ROUNDTABLE 1

Advancing Drug Discovery and Safety Assessment with AI/ML: Where we are and where we're going.

- Enhancing Drug Design – Optimizing Drug Concepts from Day 1
- Predictive Modeling for DMPK/ADME/Tox- Moving Away from In Vivo Models
- Continuous Learning Systems- Harnessing AI/ML for Reverse Translation



Claudette Fuller
Vice President, Head of Non-Clinical Safety & Toxicology
Genmab

ABOUT THE SPEAKER
Speaker TBC

10:00 - 11:05 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

Integrating breakthroughs in In Silico, In Vivo And In Vitro Pharmacology To Enhance ADMET Modeling



- What do you view as the critical breakthroughs which are (or will) drive changes in prediction and evaluation of DMPK & toxicology properties?
- Which of the new technologies do you believe are working well and which are you finding or predicting will require improvement?
- What are you finding is the greatest integration or technology challenge to reliable, cost-effective, global assessments of NCE DMPK and toxicology assessments?
- Where should innovation in this field focus today and in the future?



Steven Ring
Senior Research Scientist II,
Drug Metabolism and Pharmacokinetics
Curia



ABOUT THE SPEAKER
Speaker TBC

12:15 - 13:15 ET ROUNDTABLE 3

Exploring the use of organ-on-a-chip and other microphysiological systems for high-throughput toxicity screening, ADME studies, and prediction of drug safety profiles



Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION
[See Page 6](#)

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING EAST COAST USA 2024

14th May 2024, Tuesday Hyatt Regency Princeton

15:10 - 16:10 ET ROUNDTABLE 4

Artificial Intelligence, ADME/Tox prediction, PBPK modeling, and Data Management Strategies for early drug development



- AI/ML for drug design and preclinical development
- In silico ADME/Tox predictions versus wet-lab discovery DMPK for drug candidate nomination
- PBPK modeling in preclinical drug development
- Data management workflows for keeping track of ADME/Tox & Pharmacology data
- How in silico tools can expedite the preclinical development of drug candidates in preparation for IND submission and first-in-human trials.



Ernane Souza, PhD, RPh
Assistant Director, Translational PKPD and DMPK
Supernus Pharmaceuticals Inc

ABOUT THE SPEAKER
Speaker TBC

16:10 - 16:30 ET AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 ET PANEL DISCUSSION
[See Page 6](#)

17:00 - 18:00 ET DRINKS & CANAPES RECEPTION



BOOK NOW!

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com
Proventa International

[@proventaintl](https://twitter.com/proventaintl)
[@proventainternational](https://www.linkedin.com/company/proventainternational)



Event Day

TRACK 3 In Vivo and In Vitro Pharmacology

A primary source of drug candidate trial failure is attributed to inadequate efficacy and safety profiles. This track serves to highlight key topics and pressing challenges within the areas of drug metabolism, biotransformation and drug toxicity.

**DRUG DISCOVERY BIOLOGY
& BIOINFORMATICS**
STRATEGY MEETING EAST COAST USA 2024
14th May 2024, Tuesday Hyatt Regency Princeton

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
[See Page 6](#)

09:00 - 10:00 ET ROUNDTABLE 1

Latest approaches and trends for improving nonclinical studies

- Identifying appropriate human cell based models in 2D or 3D/organoids for preclinical studies;
- Identifying the rein of using animal models in pre-clinical testing and combining current in vitro technique to achieve desired result;
- What are the latest biomarker studies that can be utilized for complex diseases?
- Evaluating complex human cell based models and MicroPhysiological Systems (MPS) in combination with other techniques to address the problem of heterogeneous diseased population;
- Anticipating the future of In vivo and In vitro pharmacology for diseases such as cancer, neurodegeneration, and rare diseases



Angela L. Huang
Founder and President
Tempo Bioscience

ABOUT THE SPEAKER

Tempo Bioscience focuses on developing human stem cell (human iPSC technology) based 2D&3D cell models and biosensor-incorporated platform technologies for the biotech-pharmaceutical industry. Angela is listed as an inventor on numerous patents and has published in journals such as Nature. She received her scientific training from University of California, Berkeley, University of California, San Diego, and University of California, San Francisco.

10:00 - 11:05 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

Identifying the rein of using animal models in pre-clinical testing and combining current in vitro technique to achieve desired result



Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

12:15 - 13:15 ET ROUNDTABLE 3

Tackling In Vivo Complexity: Strategies for Overcoming Assay Challenges

- Reliably predicting in vivo efficacy from in vitro assays
- How to more efficiently define your drug discovery path to human disease
- Challenges in your in vitro assays
- Challenges in your in vivo assays



Marcie Glicksman
VP Biology
EnClear Therapies

ABOUT THE SPEAKER
[See Page 7](#)

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION
[See Page 6](#)

15:10 - 16:10 ET ROUNDTABLE 4

In vitro, organoid, and organ-on-chip tools in drug discovery



Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

16:10 - 16:30 ET AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 ET PANEL DISCUSSION
[See Page 6](#)

17:00 - 18:00 ET DRINKS & CANAPES RECEPTION



BOOK NOW!

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com
Proventa International

[@proventaintl](https://twitter.com/proventaintl)
[@proventainternational](https://www.linkedin.com/company/proventainternational)

PROVENTA
INTERNATIONAL

Event Day

TRACK 4

In Silico Biology / AI & ML / Blockchain and Bioinformatics / Data Integration & Data Mining

The utility of computational methods is widely used in various stages of drug discovery and development. From aiding target ID & validation, limiting the use of animal models in pharmacology to aiding rational drug design, this track will explore novel approaches and application of in silico techniques to maximize productivity towards clinical success.

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING EAST COAST USA 2024

14th May 2024, Tuesday Hyatt Regency Princeton

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
[See Page 6](#)

09:00 - 10:00 ET ROUNDTABLE 1

Harnessing the promise of generative AI to transform drug discovery hence forward

- LLMs provide unprecedented access to query and reason across large textual datasets (literature, patents, protocols), impacting pharma R&D from target ID and validation, to IND readiness, to trial protocol optimization, and beyond
- Beyond textual LLMs, foundational genAI models for DNA/RNA/protein sequence are accelerating lab screening and automation of DBTL (design, build, test, learn) cycles in "techbio" companies
- Foundational genAI models are beginning to be built (and demonstrate utility) in other patient-specific data domains: imaging, gene expression, proteomics, biomarkers, EHR/RWD, and others.
- GenAI is increasingly being used for clinical trial protocol planning, feasibility, and even operational awareness



Aaron Mackey
Former SVP, AI & Data Science
Sonata Therapeutics

ABOUT THE SPEAKER

Throughout his career, Aaron has specialized in developing advanced statistical models to decipher complex biological signals from vast genomics, clinical RWE, and clinical trial datasets. He focuses on integrating multiple datasets to enhance insights and uncover hidden relationships, and to translate these findings into actionable insights that inform decisions and drive strategies.

10:00 - 11:05 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

Leveraging AI, target selection technologies/strategies and infrastructure tools to support computational biology

- How are targets selected within current computational biology methods?
 - What would the output of a typical decision look like?
 - An entire proteome? Or by therapeutic class? CNS-only? How are
- What sources of data are available to develop ML, LLP and other apps for target selection and how are they accessed?
 - Public or private, GWAS, clinical sample analysis, various 'omes
 - How are they integrated into early target selection workflows? How are they mined (automated or manual searching)
- What specific computational methods are being used for target selection?
 - LLP, traditional ML or DL? Is there enough data to support modeling?
- What experimental methods are used to verify predictions or for screening for targets?
 - Cell imaging, chemical probes (protacs, glues, photoaffinity labeling, others)



Douglas Kitchen
Research Fellow, Medicinal Chemistry
Curia

ABOUT THE SPEAKER

Speaker TBC

12:15 - 13:15 ET ROUNDTABLE 3

Current adoption and best use of disruptive techs (blockchain, AI, and ML) in drug discovery and development

- How could the implementation of disruptive techs enhance the process of drug development?
- How can disruptive techs accelerate the drug discovery process?
- How could disruptive techs support collaborative drug research?
- How do disruptive techs play a role in personalized medicine?
- What would be the opportunity cost for not adopting disruptive techs?



Frank Leu
Founder & Managing Member/ Managing Member
BioPharMatrix LLC/ Novapeutics LLC

ABOUT THE SPEAKER

Frank Leu is a co-founder of Novapeutics for developing a first-in-class small molecule beta-cell restoration curing type 2 diabetes. Prior, Frank was at a specialty pharma, Verto Institute developing better antibody based biologic therapeutics for treating the neuroendocrine cancer. Frank is a Pharmacology graduate of Cornell Graduate School of Medical Sciences, and a post doc in a Howard Hughes Medical Institute laboratory at the Rockefeller University. He is an adjunct professor at the Thomas Jefferson University in the department of pharmacology. Frank also found BioPharMatrix providing innovative solutions to life science organizations, serving as an advisor to the Pennovations center, thought leader in the blockchain architecture adoption in drug development with publications and over 50 invited speaking events since 2017. Frank has served as advisor to the board, planning committee, chairman, speaker, and moderator for life-sciences and drug development events.

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION
[See Page 6](#)

15:10 - 16:10 ET ROUNDTABLE 4

Leveraging AI to Accelerate Drug Discovery and Development

- AI-Powered Drug Design and Development: Explore the use of AI to design new drugs, optimize lead compounds, and predict chemical properties, focusing on deep learning models and their growing role in virtual screening.
- In Silico Biology for Preclinical Analysis: Understand how in silico biology can simulate biological systems to study drug-target interactions and predict the pharmacodynamics and pharmacokinetics of new drug candidates, helping reduce the time and cost of preclinical trials.
- AI-Driven Drug Repurposing: Discuss how AI models can identify existing drugs for new therapeutic uses by analyzing vast data sets, speeding up discovery of new treatments and reducing overall drug development costs.
- Ethics and Safety in AI-Driven Drug Development: Discuss data privacy, accuracy and biases in AI models, and the impact of AI-driven decisions on patient safety and outcomes.
- Integration of AI with Traditional Drug Development: Explore strategies for integrating AI and machine learning tools with conventional drug development processes.
- Role of Large Language Models (LLMs) in Drug Discovery: Examine how LLMs can be used to automate manual tasks, create knowledge graphs, and streamline information retrieval. LLMs facilitate collaboration by making information widely available, reducing the barriers to accessing key data, and improving the efficiency of research and drug development processes.



Abhijat Vatsyayan
Head of Artificial Intelligence
Taiho Oncology

ABOUT THE SPEAKER

Trained as an aerospace engineer, Abhijat has had a career spanning over 23 years most of it dedicated to helping to bring life-extending medicines to patients through the use of technology. In this 20+ years working at pharmaceutical companies, he collaborates with individuals from diverse backgrounds, applying analytical, design, and creative problem-solving skills to the complex challenge of drug development. Abhijat also has a foundational understanding of artificial intelligence, including machine learning, and has built simplified deep-learning frameworks to educate and present machine-learning concepts. Finally, he is also a proud co-founder of multiple failed startups.

16:10 - 16:30 ET AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 ET PANEL DISCUSSION
[See Page 6](#)

17:00 - 18:00 ET DRINKS & CANAPES RECEPTION

BOOK NOW!

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com
Proventa International

@proventaintl
@proventainternational





Event Day

TRACK 5

Strategic Partnerships, Investment & Collaborations

Bringing together Managing Partners & C-level executives from investment firms supporting innovation in the clinical trial process, strategies from pharma companies and corporate arms with a vested interest in driving this innovation. It comes with the purpose of identifying and collaborating with potential drug development partners whilst addressing industry challenges in this area

DRUG DISCOVERY BIOLOGY
& BIOINFORMATICS

STRATEGY MEETING EAST COAST USA 2024

14th May 2024, Tuesday Hyatt Regency Princeton



09:00 - 10:00 ET

ROUNDTABLE 1

Forming Strategic Partnerships: Collaboration or M&A?



- Understand your strengths and weaknesses
 - Complementarities
 - Common Goals
 - Compatibility
 - Change
- Establish the business goals for partnership
- Develop objectives
- Dedicated function or engaging a consulting group?



Nikolaos Tezapsidis
President & CEO
Neurotez

ABOUT THE SPEAKER

Dr. Tezapsidis founded Neurotez in 2004. He is President and Chief Executive Officer and Chairman of the Board of Directors and has held these positions since the company was incorporated in 2005. Nikolaos has successfully raised funds primarily through non-dilutive grant sources, but also through equity-based deals. While building the company, he recruited top talent, maintaining top notch research and development programs and establishing a strong patent portfolio (more than 20 patents globally are either pending or issued). Having held several positions at a number of prominent academic institutions, Dr. Tezapsidis has more than 18 years of international biomedical research experience. Prior to forming Neurotez, Dr. Tezapsidis served as a scientific consultant to biotechnology investors, providing highly regarded expertise



11:10 - 12:10 ET

ROUNDTABLE 2

Strategic Partnerships, Investment & Collaborations in drug development



- Explore collaborations with pharmaceutical companies as Strategic Partnerships.
- Identify potential investors, including venture capitalists and angel investors, to secure funding.
- Forge partnerships with academic institutions to access cutting-edge research, expertise, and facilities.
- Explore collaborations with tech companies to use and incorporate new technologies.
- Establish global partnerships with international organizations and regulatory bodies to navigate complex regulatory landscapes.



Frank Leu
Founder & Managing Member/ Managing Member
BioPharMatrix LLC/ Novapeutics LLC

ABOUT THE SPEAKER

See Page 7



12:15 - 13:15 ET

ROUNDTABLE 3

Challenges of developing ADCs and Immunomodulatory Bispecific Biologics



Speaker TBC

ABOUT THE SPEAKER

Speaker TBC



15:10 - 16:10 ET

ROUNDTABLE 4

Fundraising and Partnership Opportunities in the current BioPharma Industry



- What are the current strategies for Biotech startups to fundraise? Are the strategies different when internal pipelines focus on preclinical assets vs. clinical development candidates? Are the strategies different between Biotech tools/devices vs. Biotech therapeutics?
- What are the current partnership opportunities in the ecosystem? Are there innovative approaches?
- How is the Biotech-Pharma industry changing? Is it changing or evolving?



Angela L. Huang
Founder and President
Tempo Bioscience

ABOUT THE SPEAKER

See Page 9

BOOK NOW!

proventainternational.com



UK: +44 (0)208 124 6417
US: +1 (617) 340 2564



info@proventainternational.com



Proventa International




@proventaintl



@proventainternational





**Find your new partner,
explore our digital storefronts**

www.pharmafeatures.com



**Contact us to discuss how we can help generate
growth for your business**

Dex Marco Guibelondo

*Marketing Content Writer, Proventa International
Editor-in-Chief, PharmaFEATURES*

dex@proventainternational.com

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS STRATEGY MEETING EAST COAST USA 2024

Tuesday 14th May 2024 Hyatt Regency Princeton

**Delegate
Price**

\$699

*Pharma/Biotech/
Academia

**Vendor/
Service
Provider**

\$2999

HYATT REGENCY

Hotel & Venue



Hyatt Regency Princeton

Hyatt Regency Princeton offers a convenient location close to Route 1 and the Princeton Junction Train Station, making it the perfect location to explore the area. Business travelers will enjoy thoughtful amenities, such as large work desks with enhanced lighting and free Wi-Fi.

BOOK NOW!

We only have limited rooms available!

[Hotel Details >](#)

[Map & Directions >](#)



OUR FACE TO FACE MEETING IN MAY 2024

STRATEGY
MEETING
EAST COAST USA

Hyatt Regency
Princeton

MAY 14

DRUG DISCOVERY BIOLOGY
& BIOINFORMATICS
STRATEGY MEETING EAST COAST USA 2024

MAY 15

MEDICINAL
CHEMISTRY
STRATEGY MEETING
EAST COAST USA 2024

MAY 16

CLINICAL OPERATIONS &
CLINICAL TRIAL SUPPLY CHAIN
STRATEGY MEETING EAST COAST USA 2024



STRATEGY
MEETING
WEST COAST USA

Hard Rock Hotel
San Diego

MAY 21

DRUG DISCOVERY BIOLOGY
& BIOINFORMATICS
STRATEGY MEETING WEST COAST USA 2024

MAY 22

MEDICINAL
CHEMISTRY
STRATEGY MEETING
WEST COAST USA 2024

MAY 23

CLINICAL OPERATIONS &
CLINICAL TRIAL SUPPLY CHAIN
STRATEGY MEETING WEST COAST USA 2024

Visit us on our website to know
more about our meetings
www.proventainternational.com